Faruqi & Faruqi, LLP Announces Investigation of Immucor, Inc.

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Immucor, Inc. (“Immucor” or the “Company”) (Nasdaq: BLUD) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to investment funds managed by TPG Capital in a deal with a fully diluted equity value of about $1.973 billion. Under the terms of the proposed transaction, Immucor shareholders will receive $27 in cash, while, according to Yahoo! Finance, at least one financial analyst has set a price target of $28 for Immucor. The proposed transaction is structured as a tender offer and may be effectuated without a shareholder vote.